[Effect of downregulation of prostate cancer antigen-1 expression on malignant biological behavior of prostate cancer LNCaP cells].
OBJECTIVE
To detect the expression of prostate cancer antigen-1 (PCA-1) in prostate cancer, and to analyze the effects of downregulation of PCA-1 expression on malignant biological behavior of prostate cancer LNCaP cells, and to explore their possible molecular mechanisms.


METHODS
PCA-1-siRNA and control siRNA were transfected into LNCaP cells with lipofectamine 2000. The cell cycle, proliferation and migration were determined by methyl thiazolyl tetrazolium (MTT) assay, flow cytometry and Transwell chambers, respectively. Western blotting was used to detect the expression of cyclin E, matrix metallopeptidase 9 (MMP-9) and p21. Immunohistochemistry was used to detect the expression of PCA-1 protein in 126 cases of prostate cancer and 88 cases of benign prostatic hyperplasia (BPH).


RESULTS
The positive rate of PCA-1 expression was 77.8% (98/126) in prostate cancer, and 10.2% (9/88) in BPH, and its expression was not significantly related to age, prostate specific antigen (PSA), Eastern Cooperative Oncology Group (ECOG) score (P > 0.05), and was associated with Gleason score, TNM staging and bone metastasis (P < 0.05). Downregulation of PCA-1 expression inhibited cell proliferation, arrested cell cycle at S phase and decreased cell migration of LNCaP cells. The downregulation of PCA-1 expression decreased the expression of Bcl-xl, cyclin E and MMP-9 proteins, but increased the expression of p21 proteins.


CONCLUSIONS
PCA-1 may play an important role in the development of prostate cancer. The downregulation of PCA-1 expression can lead to changes in the proliferation, cell cycle and migration of prostate cancer LNCaP cells, and these effects may be associated with the decrease of Bcl-xl, cyclin E and MMP-9 proteins and increase of p21 protein.
Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Email: liubq76@yahoo.com.cn.
Bing-qian
BQ
Liu
Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Yi-kun
YK
Wang
Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Yu-dong
YD
Wu
Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Jin-xing
JX
Wei
Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Xin
X
Li
D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000235:genetics / Q000378:metabolism*; D002453:Cell Cycle; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D019927:Cyclin E / Q000378:metabolism; D015536:Down-Regulation; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D008875:Middle Aged; D009367:Neoplasm Staging; D015513:Oncogene Proteins / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D016283:Proto-Oncogene Proteins p21(ras) / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics; D014162:Transfection; D051020:bcl-X Protein / Q000378:metabolism
D000951:Antigens, Neoplasm; C494811:BCL2L1 protein, human; C475820:CCNE1 protein, human; D019927:Cyclin E; D015513:Oncogene Proteins; C505096:PCA-1 antigen, human; D034741:RNA, Small Interfering; D051020:bcl-X Protein; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9; D016283:Proto-Oncogene Proteins p21(ras)